Positive Response to Trastuzumab in a Case of HER2-Overexpressing Metastatic Gastric Cancer that Presented as Severe Thrombocytopenia

Publisher： Karger

E-ISSN： 2296-5262|34|11|621-624

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.11, 2011-10, pp. : 621-624

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab plus Chemotherapy in Gastric Cancer Overexpressing HER-2 and EGFR: A Case Report

By  

Oncology Research and Treatment, Vol. 34, Iss. 1-2, 2011-01 ,pp. : 42-45

Karger

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 505-508

Karger

Access to resources Recommend Favorite

Successful Treatment of a Patient with HER2-Positive Metastatic Gastric Cancer with Third-Line Combination Therapy with Irinotecan, 5-Fluorouracil, Leucovorin and Trastuzumab (FOLFIRI-T)

By  

Oncology Research and Treatment, Vol. 34, Iss. 10, 2011-09 ,pp. : 548-551

Karger

Access to resources Recommend Favorite

Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 582-586

Karger

Access to resources Recommend Favorite